<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03247010</url>
  </required_header>
  <id_info>
    <org_study_id>Radium-Trombocyt</org_study_id>
    <nct_id>NCT03247010</nct_id>
  </id_info>
  <brief_title>Bone Marrow Suppression and Recovery During Radionuclide Treatment</brief_title>
  <official_title>Characterization of Bone Marrow Suppression and Recovery During Radionuclide Treatment Using Functional Tests of Thrombocytes and Hemostasis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Rigshospitalet, Denmark</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Rigshospitalet, Denmark</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Radium-223-dichloride is approved therapy for patients with metastatic castration-resistant
      prostate cancer and bone metastases. Therapy is administered intravenously every 4 weeks for
      up to 6 cycles. More than 20 % of patients treated at Rigshospitalet develop bone marrow
      suppression as a side effect to Radium therapy, which delays or excludes the patient from
      further oncological therapy. Especially thrombocytopenia is a frequent side-effect and can be
      long lasting.

      The aim of the study is to examine whether biomarkers of bone marrow recovery (immature
      platelets, platelet volume, reticulocytes, red cell distribution width) can predict
      development of hematological toxicity during Radium therapy. Furthermore, to investigate
      whether these biomarkers can predict recovery from toxicity in patients who develop bone
      marrow suppression during therapy.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">June 20, 2017</start_date>
  <completion_date type="Anticipated">August 1, 2020</completion_date>
  <primary_completion_date type="Anticipated">August 1, 2019</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Thrombocytopenia</measure>
    <time_frame>Within 1 year from inclusion</time_frame>
    <description>CTCAE grade 1-5</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Leucopenia</measure>
    <time_frame>Within 1 year from inclusion</time_frame>
    <description>CTCAE grade 1-5</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Anemia</measure>
    <time_frame>Within 1 year from inclusion</time_frame>
    <description>CTCAE grade 3-5</description>
  </secondary_outcome>
  <enrollment type="Anticipated">100</enrollment>
  <condition>Castration-resistant Prostate Cancer</condition>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Blood sampling</intervention_name>
    <description>Blood samples are taken before each cycle of Radium 223</description>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Patients with metastatic castration-resistant prostate cancer, who initiate therapy with
        Radium-223 at Rigshospitalet, Copenhagen, Denmark
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Metastatic castration resistant prostate cancer

          -  Planned to initiate Radium therapy

          -  Age &gt; 18 years

          -  Able to understand study protocol and give informed consent

        Exclusion Criteria:
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jann Ø Mortensen, DMSc</last_name>
    <role>Study Director</role>
    <affiliation>Rigshospitalet, Department of Clinical Physiology, Nuclear Medicine &amp; PET</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Marie Ø Fosbøl, MD</last_name>
    <phone>+4531508808</phone>
    <email>marie.oebro.fosboel@regionh.dk</email>
  </overall_contact>
  <location>
    <facility>
      <name>Rigshospitalet</name>
      <address>
        <city>Copenhagen</city>
        <zip>2100</zip>
        <country>Denmark</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Marie Fosbøl, MD</last_name>
      <phone>+4531508808</phone>
      <email>marie.oebro.fosboel@regionh.dk</email>
    </contact>
  </location>
  <location_countries>
    <country>Denmark</country>
  </location_countries>
  <verification_date>August 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>August 7, 2017</study_first_submitted>
  <study_first_submitted_qc>August 10, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">August 11, 2017</study_first_posted>
  <last_update_submitted>August 10, 2017</last_update_submitted>
  <last_update_submitted_qc>August 10, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">August 11, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Rigshospitalet, Denmark</investigator_affiliation>
    <investigator_full_name>Marie Øbro Fosbøl</investigator_full_name>
    <investigator_title>MD, PhD student</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Prostatic Neoplasms</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

